# Gyre Therapeutics, Inc.: filings

GYRE · Nasdaq · CIK 1124105 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gyre.md) · [Financials](/companies/gyre/financials.md) · [Filings](/companies/gyre/filings.md) · [Insiders](/companies/gyre/insiders.md)

## Reports and events: 436 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 529, 8-K 282, SC 13G/A 68, 10-Q 53, 3 50, SC 13G 40, SC 13D/A 37, DEFA14A 31, 4/A 24, CT ORDER 20, 144 19, 10-K 18, 424B5 17, CORRESP 17, DEF 14A 17, UPLOAD 17, DFAN14A 15, S-8 15, S-3 12, SC 13D 12, EFFECT 11, ARS 10, 425 8, 8-K/A 7, 424B3 5, 3/A 3, PRE 14A 3, PRER14A 3, PRRN14A 3, RW 3, S-1/A 3, S-3/A 3, S-4/A 3, SCHEDULE 13D/A 3, 10-K/A 2, DEFC14A 2, PREC14A 2, 10-Q/A 1, 424B4 1, D 1, DEFM14A 1, FWP 1, PREM14A 1, S-1 1, S-1MEF 1, S-3MEF 1, S-4 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-11-05 | 16:30 ET | [8-K](/filings/0001193125-26-449985.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-449985 |
| 2026-10-22 | 16:01 ET | [8-K](/filings/0001140361-26-040506.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-040506 |
| 2026-09-01 | 09:00 ET | [8-K](/filings/0001140361-26-035189.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-035189 |
| 2026-08-26 | 09:00 ET | [8-K](/filings/0001140361-26-034401.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-034401 |
| 2026-08-07 | 17:00 ET | [10-Q](/filings/0001193125-26-340448.md) | Quarterly report, period 2026-06-30 | 0001193125-26-340448 |
| 2026-08-07 | 08:00 ET | [8-K](/filings/0001193125-26-339223.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-339223 |
| 2026-07-16 | 16:35 ET | [8-K](/filings/0001140361-26-028716.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-028716 |
| 2026-07-15 | 17:09 ET | [8-K/A](/filings/0001140361-26-028564.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-028564 |
| 2026-06-16 | 06:30 ET | [8-K](/filings/0001140361-26-025324.md) | 5.07 Shareholder vote results | 0001140361-26-025324 |
| 2026-06-02 | 06:09 ET | [8-K](/filings/0001140361-26-023625.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-023625 |
| 2026-05-14 | 17:25 ET | [8-K](/filings/0001140361-26-021360.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-021360 |
| 2026-05-12 | 17:03 ET | [8-K](/filings/0001140361-26-020845.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-020845 |
| 2026-05-08 | 16:16 ET | [10-Q](/filings/0001193125-26-214676.md) | Quarterly report, period 2026-03-31 | 0001193125-26-214676 |
| 2026-05-07 | 06:01 ET | [SCHEDULE 13D/A](/filings/0001140361-26-019395.md) | Ownership report, active investor, amended | 0001140361-26-019395 |
| 2026-05-06 | 21:53 ET | [SCHEDULE 13D/A](/filings/0001140361-26-019388.md) | Ownership report, active investor, amended | 0001140361-26-019388 |
| 2026-05-06 | 20:46 ET | [SCHEDULE 13D/A](/filings/0001140361-26-019380.md) | Ownership report, active investor, amended | 0001140361-26-019380 |
| 2026-05-07 | 20:30 ET | [8-K](/filings/0001193125-26-209789.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-209789 |
| 2026-05-04 | 09:12 ET | [8-K](/filings/0001140361-26-018716.md) | 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-018716 |
| 2026-04-27 | 16:30 ET | [DEF 14A](/filings/0001140361-26-017124.md) | Proxy statement, period 2026-06-10 | 0001140361-26-017124 |
| 2026-04-17 | 08:55 ET | [8-K/A](/filings/0001140361-26-015307.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-26-015307 |
| 2026-03-23 | 07:51 ET | [8-K](/filings/0001140361-26-010654.md) | 8.01 Other events | 0001140361-26-010654 |
| 2026-03-13 | 16:31 ET | [10-K](/filings/0001193125-26-106251.md) | Annual report, period 2025-12-31 | 0001193125-26-106251 |
| 2026-03-12 | 06:31 ET | [8-K](/filings/0001140361-26-009115.md) | 7.01 Regulation FD disclosure | 0001140361-26-009115 |
| 2026-03-12 | 20:00 ET | [8-K](/filings/0001193125-26-102700.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-102700 |
| 2026-03-02 | 09:24 ET | [8-K](/filings/0001140361-26-007249.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-007249 |
| 2026-01-05 | 07:06 ET | [8-K](/filings/0001140361-26-000253.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-000253 |
| 2025-11-07 | 16:16 ET | [10-Q](/filings/0001193125-25-272383.md) | Quarterly report, period 2025-09-30 | 0001193125-25-272383 |
| 2025-11-07 | 21:55 ET | [8-K](/filings/0001193125-25-270524.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-270524 |
| 2025-09-10 | 09:00 ET | [8-K](/filings/0001140361-25-034506.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-034506 |
| 2025-08-22 | 07:05 ET | [8-K](/filings/0001140361-25-032295.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-032295 |
| 2025-08-11 | 17:07 ET | [10-Q](/filings/0000950170-25-106644.md) | Quarterly report, period 2025-06-30 | 0000950170-25-106644 |
| 2025-08-11 | 16:00 ET | [8-K](/filings/0000950170-25-106525.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-106525 |
| 2025-06-06 | 19:27 ET | [8-K](/filings/0001140361-25-021612.md) | 5.07 Shareholder vote results | 0001140361-25-021612 |
| 2025-05-23 | 16:46 ET | [8-K](/filings/0001140361-25-020353.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-25-020353 |
| 2025-05-22 | 16:01 ET | [8-K](/filings/0001140361-25-020157.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-25-020157 |
| 2025-05-09 | 16:30 ET | [10-Q](/filings/0000950170-25-068089.md) | Quarterly report, period 2025-03-31 | 0000950170-25-068089 |
| 2025-05-09 | 20:30 ET | [8-K](/filings/0000950170-25-067452.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-067452 |
| 2025-04-28 | 07:05 ET | [8-K](/filings/0001140361-25-015880.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-015880 |
| 2025-04-21 | 17:23 ET | [DEF 14A](/filings/0001140361-25-014779.md) | Proxy statement, period 2025-06-04 | 0001140361-25-014779 |
| 2025-03-17 | 16:15 ET | [10-K](/filings/0000950170-25-040279.md) | Annual report, period 2024-12-31 | 0000950170-25-040279 |
| 2025-03-17 | 16:05 ET | [8-K](/filings/0000950170-25-040232.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-040232 |
| 2025-02-18 | 06:01 ET | [8-K](/filings/0001140361-25-004957.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-004957 |
| 2025-01-06 | 07:05 ET | [8-K](/filings/0001140361-25-000292.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-25-000292 |
| 2024-11-27 | 16:25 ET | [8-K](/filings/0001140361-24-047980.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001140361-24-047980 |
| 2024-11-13 | 16:05 ET | [10-Q](/filings/0000950170-24-126306.md) | Quarterly report, period 2024-09-30 | 0000950170-24-126306 |
| 2024-11-13 | 20:45 ET | [8-K](/filings/0000950170-24-125869.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125869 |
| 2024-09-06 | 08:31 ET | [SC 13D](/filings/0001140361-24-040318.md) | Ownership report, active investor | 0001140361-24-040318 |
| 2024-09-06 | 08:15 ET | [SC 13D](/filings/0001140361-24-040313.md) | Ownership report, active investor | 0001140361-24-040313 |
| 2024-08-13 | 16:05 ET | [10-Q](/filings/0000950170-24-096159.md) | Quarterly report, period 2024-06-30 | 0000950170-24-096159 |
| 2024-08-13 | 21:04 ET | [8-K](/filings/0000950170-24-095687.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095687 |

Page 1 of 9. [Older](/companies/gyre/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 5, 2026, 18:44 ET. No prices; not investment advice.